CureVac/$CVAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CureVac
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Ticker
$CVAC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
904
ISIN
NL0015436031
Website
CureVac Metrics
BasicAdvanced
$1.2B
5.85
$0.94
2.49
-
Price and volume
Market cap
$1.2B
Beta
2.49
52-week high
$5.72
52-week low
$2.37
Average daily volume
1.7M
Financial strength
Current ratio
7.654
Quick ratio
7.327
Long term debt to equity
4.976
Total debt to equity
5.78
Profitability
EBITDA (TTM)
282.666
Gross margin (TTM)
87.62%
Net profit margin (TTM)
34.50%
Operating margin (TTM)
43.61%
Effective tax rate (TTM)
13.61%
Revenue per employee (TTM)
$680,660
Management effectiveness
Return on assets (TTM)
19.93%
Return on equity (TTM)
33.04%
Valuation
Price to earnings (TTM)
5.847
Price to revenue (TTM)
2.01
Price to book
1.91
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
7.352
Free cash flow yield (TTM)
13.60%
Free cash flow per share (TTM)
74.81%
Growth
Revenue change (TTM)
787.60%
Earnings per share change (TTM)
-165.62%
3-year revenue growth (CAGR)
64.65%
3-year earnings per share growth (CAGR)
-21.81%
What the Analysts think about CureVac
Analyst ratings (Buy, Hold, Sell) for CureVac stock.
Bulls say / Bears say
BioNTech's acquisition of CureVac for $1.25 billion in an all-stock deal is expected to enhance BioNTech's mRNA-based cancer immunotherapy capabilities, potentially increasing CureVac's valuation. (reuters.com)
CureVac's CVGBM cancer vaccine demonstrated promising immune responses in a Phase 1 study for glioblastoma, with 77% of evaluable patients showing antigen-specific T-cell responses, indicating strong potential in cancer immunotherapy. (stocktitan.net)
The European Patent Office upheld the validity of CureVac's patent EP 3 708 668 B1, strengthening its intellectual property position in mRNA technology and potentially enhancing its market competitiveness. (stocktitan.net)
CureVac reported a net loss of €72.54 million in Q2 2024, reflecting ongoing financial challenges that may impact investor confidence. (google.com)
The company missed earnings expectations in Q4 2023, reporting an EPS of -41 cents against an estimated -20 cents, raising concerns about its financial performance. (markets.businessinsider.com)
CureVac's stock price has experienced significant volatility, with a 52-week range between €2.37 and €5.72, indicating potential instability and risk for investors. (barchart.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CureVac Financial Performance
Revenues and expenses
CureVac Earnings Performance
Company profitability
CureVac News
AllArticlesVideos
CureVac Announces Voting Results of General Meeting
Accesswire·2 weeks ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
GlobeNewsWire·3 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $1.2B as of July 11, 2025.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 5.85 as of July 11, 2025.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.